PARP1 and neoplasm: As studies in several tumor types now support the concept of HDAC-inhibitors mimicking a BRCA-mutated phenotype and enhancing the tumoricidal effects of PARP inhibitors [92,93,94], this concept warrants exploration in PDAC patients, particularly as the FDA-approved HDAC inhibitor Panobinostat has shown similar results in preclinical testing [95].